# Safety and Efficacy of Faricimab in Patients With NPDR

> **NCT05681884** · PHASE2 · COMPLETED · sponsor: **Greater Houston Retina Research** · enrollment: 179 (actual)

## Conditions studied

- Non-Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** Faricimab

## Key facts

- **NCT ID:** NCT05681884
- **Lead sponsor:** Greater Houston Retina Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-16
- **Primary completion:** 2026-02-26
- **Final completion:** 2026-02-26
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05681884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05681884, "Safety and Efficacy of Faricimab in Patients With NPDR". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05681884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*